Evidence map›Paper›PMID 42705011›Full record

ArticleClinics (Sao Paulo, Brazil)2026

S100A8/A9 as a novel predictor for severe Mycoplasma pneumoniae pneumonia in children: A prospective observational study.

Zihui Liu, Lihui Gao, Yun Cui, Yiping Zhou, Xi Xiong, Chunxia Wang, Yucai Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zihui LiuDepartment of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Lihui GaoCore Facilities and Transformation Center, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yun CuiDepartment of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Laboratory of Critical Care Translational Medicine, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China.
Yiping ZhouDepartment of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xi XiongDepartment of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Laboratory of Critical Care Translational Medicine, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China.
Chunxia WangCore Facilities and Transformation Center, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Laboratory of Critical Care Translational Medicine, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China. Electronic address: karencx0465@163.com.
Yucai ZhangDepartment of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Laboratory of Critical Care Translational Medicine, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China. Electronic address: zyucai2018@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe calprotectin S100A8/A9 complex is released by stimulating neutrophils and monocytes, and inducing cytokine secretion, modulating the inflammatory response. The aim of present study was to investigate the role of S100A8/A9 in Severe Mycoplasma Pneumoniae Pneumonia (SMPP). STUDY

designWe conducted a prospective study on pediatric Mycoplasma Pneumoniae Pneumonia (MPP) from December 2023 to May 2024. Patients were categorized into the SMPP group and non-SMPP (Non-Mycoplasma Pneumoniae Pneumonia, NSMPP) group based on hospitalization. Matched subgroups were formed according to age, sex, co-infection.

resultsA total of 132 patients were included. Serum S100A8/A9 levels in SMPP were significantly higher than those in NSMPP group (5.877 [3.202, 9.257] vs. 4.349 [2.495, 6.902] μg/mL, p = 0.049). Both C-Reactive Protein (CRP) and Lactate Dehydrogenase (LDH) levels were significantly elevated in SMPP compared to NSMPP groups (p = 0.009 and p = 0.036, respectively). Multivariate logistic regression analysis revealed that S100A8/A9 levels is a key predictor for SMPP. The Area Under the ROC Curve (AUC) for S100A8/A9 levels in predicting SMPP was 0.601 (95% CI: 0.512‒0.685). Post-matching, the AUC increased to 0.714 (95% CI: 0.549‒0.845), with an optimal cutoff value of S100A8/A9 at 4.067 μg/mL, a sensitivity of 75%, and a specificity of 70%. Additionally, the AUCs for CRP and LDH were 0.701 and 0.690, respectively. The combined variables of S100A8/A9 and CRP achieved an AUC of 0.742 (95% CI: 0.580‒0.867), showing a relative advantage over S100A8/A9 alone.

conclusionOur findings indicate that serum S100A8/A9 is a potential adjunct biomarker for predicting severe Mycoplasma Pneumoniae Pneumonia (SMPP) in children. The conclusion is preliminary exploration and requires further validation in larger, multicenter prospective cohorts.

Indexed as

BiomarkerCalprotectin S100A8/A9ChildSevere Mycoplasma Pneumoniae Pneumonia (SMPP)

Identifiers

PMID42705011
PMCPMC13578951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.